Inactive Instrument
Northwest Biotherapeutics, Inc Stock OTC Bulletin Board
Stocks
US66737P5017
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 05-15 | Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-21 | Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic | CI |
| Market Cap | 303M 266M 245M 229M 431M 28.85B 440M 2.95B 1.14B 14.16B 1.14B 1.11B 49.29B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 400M 351M 323M 301M 567M 37.99B 579M 3.88B 1.5B 18.65B 1.5B 1.47B 64.9B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 11x |
| Free-Float |
95.04% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Alton Boynton
CEO | Chief Executive Officer | 82 | 2007-05-31 |
Linda Powers
CEO | Chief Executive Officer | 71 | 2011-06-07 |
Marnix Bosch
CTO | Chief Tech/Sci/R&D Officer | 67 | 1999-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Alton Boynton
BRD | Director/Board Member | 82 | 1997-12-31 |
Linda Powers
CHM | Chairman | 71 | 2007-05-16 |
Navid Malik
BRD | Director/Board Member | 57 | 2012-03-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.19% | +6.01% | +66.90% | +123.30% | 57.65B | |
| +0.55% | +17.77% | +80.01% | +100.93% | 55.14B | |
| +0.93% | +4.11% | -12.64% | -12.98% | 23.53B | |
| +0.36% | +3.42% | +9.61% | +407.11% | 23.11B | |
| -1.93% | +11.11% | +34.89% | -7.86% | 18.14B | |
| +0.28% | +5.36% | +36.88% | -30.23% | 16.84B | |
| -0.83% | +2.06% | +23.70% | +182.37% | 13.68B | |
| +0.14% | +9.60% | +33.31% | - | 12.97B | |
| -4.20% | +0.91% | +71.37% | +122.68% | 12.38B | |
| Average | -0.77% | +4.71% | +38.23% | +110.66% | 25.94B | |
| Weighted average by Cap. | -0.67% | +4.51% | +47.50% | +114.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 38.93M 34.18M 31.46M 29.32M 55.3M 3.7B 56.42M 378M 147M 1.82B 146M 143M 6.32B |
| Net income | - | - |
| Net Debt | 96.08M 84.36M 77.65M 72.35M 136M 9.13B 139M 934M 362M 4.48B 361M 353M 15.6B | 125M 110M 101M 94.09M 177M 11.88B 181M 1.21B 471M 5.83B 469M 459M 20.29B |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
